![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 40, 36896-36901, October 5, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Emory University School of Medicine, Atlanta, Georgia 30322
Received for publication, May 4, 2001, and in revised form, June 20, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The diabetes-induced decrease in insulin-like
growth factor-I transcription appears to be mediated by footprint
region V in exon 1. Since region V contains both an Sp1 site and an
AT-rich element that recognizes an insulin-responsive binding protein (IRBP), we tested the hypothesis that Sp1 interactions are facilitated by an IRBP. Binding of nuclear extracts to region V probes was reduced
by mutational or chemical interference with the AT-rich element.
Blocking the AT site also reduced interactions of Sp1 with region V
in vitro and blunted transactivation of region V reporter
constructs by Sp1 in vivo. Sp1 binding was enhanced by small quantities of hepatic nuclear extracts, but enhancement was
reduced by the AT mutation and abolished by a 5-base pair insertion
between the AT-rich and GC-rich sites, and transactivation by Sp1
in vivo was diminished by inserting bases between the
AT-rich and GC-rich elements. However, treating cells with insulin
increased the ability of nuclear extracts to enhance Sp1 binding. These findings indicate that the presence of the AT-rich element is essential
for the actions of Sp1 in vitro and in vivo,
and the combination of both spacing requirements and insulin
responsiveness suggests that IRBP may interact directly with Sp1.
Insulin-like growth factor-I
(IGF-I)1 is critical for
normal growth and development. A small protein similar to insulin in structure (1), IGF-I plays a broad role in cellular proliferation and
differentiation and overall tissue growth and has anabolic effects on
metabolism (reviewed in Ref. 2). IGF-I is expressed throughout the body
and acts via autocrine, paracrine, and endocrine pathways; the majority
of circulating (endocrine) IGF-I is produced by the liver (3).
Abrogation of hepatic IGF-I production in liver-specific knockout mice
resulted in a 75% drop in serum IGF-I levels, and normal growth was
maintained only by a 6-fold increase in circulating growth hormone
levels, presumably via stimulation of local IGF-I production in
extrahepatic tissues (4).
Expression of the IGF-I gene is stimulated by growth hormone,
nutritional status, and insulin (5-7). Diabetic animals display lower
levels of IGF-I protein and mRNA than normal animals, but IGF-I
levels are normalized by insulin treatment (8, 9). IGF-I expression
appears to be regulated largely at the level of gene transcription, as
nuclear run-on studies show that IGF-I gene transcription is
diabetes-responsive in rats and insulin-responsive in cultured
hepatocytes (9, 10).
Most IGF-I transcripts originate in exon 1 (11, 12), and the IGF-I gene
contains a number of DNase I-footprinted protein binding sites within
300 bp upstream and downstream of the major transcription initiation
sites (13). One of the footprinted areas, downstream region V, appears
to be critical for IGF-I regulation by insulin and diabetes status, as
deletion of this region abolishes the differential expression of IGF-I
observed in in vitro transcription assays with hepatic
nuclear extracts from normal and diabetic animals (13). Region V is a
24-bp sequence that contains a GC-rich Sp1 binding site (14) adjacent
to an AT-rich sequence with homology to the binding site for the
homeodomain family of transcription factors (reviewed in Ref. 15).
Sp1 and the related factors Sp3 and Sp4 bind to the 6-bp sequence
5'-CCGCCC (16-18). A ubiquitous factor that is relatively unregulated,
Sp1 is involved in the expression of numerous genes, including
tumor necrosis factor The homeodomain family of proteins binds to the core consensus sequence
5'-ATTA, such as that found in IGF-I region V; homeodomain proteins are
typically involved in developmental regulation of gene expression
(reviewed in Ref. 15). The region V sequence recognizes several factors
in nuclear extracts, including both Sp1 and an
insulin-responsive binding
protein (IRBP), that interacts with the AT-rich element
(14, 23). In this study, we provide evidence supporting the hypothesis
that IRBP interacts with Sp1 to stimulate binding to region V and
expression of the IGF-I gene.
Reagents--
Mediatech Cellgro cell culture medium was obtained
from Fisher, and fetal bovine serum, antibiotics, and recombinant human insulin were from Life Technologies, Inc. [ Plasmids for Transfection Experiments--
Reporter plasmids
contained tandem copies of IGF-I footprint region V in pGL3-promoter
(Promega, Madison, WI). The wtV, VmAT, and VmSp1 constructs have
previously been described (14), and the VcSp1, V+2, V+5, and V+10
reporters were generated in the same manner. Briefly, double-stranded
oligonucleotides containing the sequences listed in Table I were
phosphorylated with T4 polynucleotide kinase, self-ligated with T4 DNA
ligase, and separated on a 3% agarose gel. Bands representing 4-mers
were eluted, treated with Taq DNA polymerase to add terminal
adenine residues, subcloned into pCR2.1 (a TA cloning vector from
Invitrogen, Carlsbad, CA), and then cloned into pGL3 promoter at the
KpnI and XhoI sites. The pPacSp1 expression
plasmid, containing the strong actin promoter, was provided by Dr.
Robert Tjian (24); we generated the pPac vector control by removing the
2.1-kb Sp1 fragment from pPacSp1.
Cell Culture and Transfection--
CHO cells and HepG2 cells
were obtained from American Type Culture Collection (Manassas, VA). CHO
cells are used in many laboratories, whereas HepG2 cells are
liver-derived and, thus, more likely to be metabolically relevant to
studies of "endocrine" production of IGF-I. CHO cells were
maintained in F-12 medium containing 10% fetal bovine serum, whereas
HepG2 cells were cultured in Eagle's minimal essential medium with
10% serum. Cells were generally cotransfected at 50-60% confluence
using 2 µg of reporter plasmid and 0.5 µg of expression plasmid per
35-mm well. CHO cells were transfected by the calcium phosphate method
(5 Prime Hepatic Nuclear Extract Preparation--
The Emory University
Animal Care and Use Committee approved all animal use. Male
Sprague-Dawley rats were obtained from Charles River Laboratories
(Raleigh, NC). Nuclear extracts from livers of normal rats were
prepared using a modification of the method previously described (25).
Briefly, livers were homogenized in an anaerobic tissue processor in 2 M sucrose with 1% dry milk and filtered through
cheesecloth, and nuclei were pelleted by centrifugation through a 2 M sucrose cushion. Nuclei were resuspended in storage
buffer (20 mM Tris-Cl, pH 7.9, 75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT, 0.125 mM
phenylmethylsulfonyl fluoride, and 50% glycerol) and repelleted,
followed by lysis in NUN buffer (1.1 M urea, 0.33 M NaCl, 1.1% Nonidet P-40, 27.5 mM HEPES, pH
7.6, 11% glycerol, 1 mM DTT, 1.1% aprotinin, 0.77 µg/ml
leupeptin, and 0.77 µg/ml pepstatin A).
Nuclear Extracts from Cultured Cells--
Chinese hamster ovary
cells that were stably transfected with the insulin receptor (CHO-IR
cells) were obtained from Drs. Barry Goldstein and Morris White.
Insulin was dissolved in 10 Gel Mobility Shift Assays--
Radiolabeled double-stranded
oligonucleotides (50,000 cpm/reaction) were incubated with nuclear
extracts in 20 µl of binding buffer containing 5% glycerol, 1 mM EDTA, 50 mM NaCl, 10 mM Tris-Cl pH 7.5, 1 mM DTT, and 1 µg of poly(dI-dC) (Roche
Molecular Biochemicals) for 30 min at 25 °C. Reactions usually
contained either 3-5 µg of rat liver nuclear extracts or 1-2
footprinting units of rhSp1 with 1 µg of bovine serum albumin. When
included, berenil was incubated with the probe for 30 min before the
addition of protein at a final berenil concentration of 50 µM. Facilitation experiments contained ~0.3 µg of
nuclear extracts and/or 0.06 footprinting units of rhSp1with 1 µg of
bovine serum albumin. Samples were subjected to electrophoresis on
4.5% polyacrylamide gels in TGE buffer (25 mM Tris, 190 mM glycine, and 1 mM EDTA) at 4 °C and 150 volts for 3 h followed by autoradiography. All experiments were
repeated at least three times.
Statistics--
Where appropriate, results are expressed as the
mean ± S.E. Statistical significance was assessed by Student's
t test.
Binding to IGF-I Region V Is Reduced by Interference with the
AT-rich Element--
Footprint region V is located ~150 bp
downstream from a major transcription initiation site in exon 1 (initiation site 3 (11)) and contains both an AT-rich sequence and an
adjacent GC-rich element that is recognized by Sp1 (Table
I and Ref. 14). Gel shift studies with
hepatic nuclear extracts and a wild type region V probe (wtV, Table I)
revealed three complexes, B1, B2, and B3 (Fig. 1A,
lane 1); we previously demonstrated that B2
contains Sp1 and B3 contains Sp3 and that both interact
with the GC-rich element (14). B1 contains IRBP, an
insulin-responsive binding protein(s) that is distinct from Sp1 and
binds to the AT-rich element (23). To investigate the functional
importance of the AT-rich sequence, we conducted gel shift analyses
using a region V probe with a 4-bp mutation in the AT-rich region
(VmAT, Table I). This mutation completely abolished B1
binding and greatly reduced interactions with Sp1 and Sp3 (Fig.
1A, lane 2). Since Sp1 and Sp3 interact directly
with the GC-rich element, these observations provided the first
evidence that Sp1 and Sp3 binding depends in part on either
(a) the presence of neighboring DNA sequence elements,
and/or (b) the presence of IRBP, presumably bound to the
neighboring AT-rich element.
As a separate method of evaluating interactions involving the AT-rich
element, we performed gel shift experiments in which the probe was
treated with berenil before the addition of nuclear extracts. Berenil
binds in a non-intercalative fashion to AT-rich stretches of DNA that
are at least 4-6 bp long and blocks interactions of proteins with such
elements (27). As shown in Fig. 1B, berenil almost
completely prevented the binding of all three major complexes, indicating the importance of the AT-rich element not only for interactions with IRBP (in B1), but apparently also with
Sp1 and Sp3.
Sp1 Interactions with Region V Are Reduced by Interference with the
AT-rich Site--
To determine whether the AT-rich element might play
a direct role in Sp1 binding to region V, we used rhSp1 in gel shift
studies. Although rhSp1 showed a relatively strong interaction with the wtV probe, binding to the VmAT probe was markedly reduced (Fig. 2A, lanes 1 and
2), and no binding was observed with a control region V
probe mutated at the Sp1 site (VmSp1, lane 3). Consistent with this finding, incubation of the wtV probe with berenil before the
addition of rhSp1 also resulted in diminished binding (Fig. 2B). Mutation of the AT-rich element blunted the effect of
berenil on Sp1 binding to region V, as seen with control probes
containing the consensus Sp1 site but a mutated AT-rich element
(VmATcSp1 in Table I, data not shown). Thus, the AT-rich site is
critical not only for interactions with IRBP (in B1) but
also for efficient binding of Sp1.
We then evaluated the importance of the AT-rich element for Sp1
transactivation via region V in vivo. CHO cells were
co-transfected with reporter constructs containing three copies of the
wtV, VmAT, and VmSp1 sequences (Table I) along with an expression
vector containing Sp1 and the appropriate empty vector controls. The wtV reporter exhibited 2-fold stimulation by Sp1, and the VmSp1 reporter displayed no stimulation, as expected (Fig.
3A). However, the VmAT
reporter resulted in reduced activation by Sp1 (21% less than the wild
type reporter, p < 0.003). In other experiments, CHO
cells were treated with berenil after transfection. Blocking AT-rich
sequences in this manner also prevented activation of the wtV reporter
by Sp1 (Fig. 3B). Taken together, these findings indicate
that the AT-rich site is critical for Sp1 interactions with region V
both in vitro and in vivo.
A Factor(s) in Hepatic Nuclear Extracts Enhances Sp1 Binding to
Region V--
The presence of the AT-rich element might influence
binding and activity of Sp1 either directly or via interactions with
factors such as IRBP that bind to the AT-rich element. To test the
hypothesis that a factor(s) binding to the AT-rich site might
facilitate Sp1 binding to the adjacent GC-rich site, gel shifts were
conducted using threshold quantities of either hepatic nuclear
extracts, rhSp1, or both; these experiments utilized trace amounts of
protein to permit observation of facilitated binding, which might have been obscured by strong bands resulting from the use of higher concentrations of either component. Although nuclear extracts alone and
rhSp1 alone showed negligible binding to the wtV probe, the combination
produced robust binding (Fig. 4,
lanes 2-4). Consistent with the studies shown in Figs.
1A and 2A, the enhanced binding was greatly
reduced with the VmAT probe (Fig. 4, lanes 5-7). The enhanced complex is most likely Sp1 and not IRBP, as the VmAT probe
completely eliminates IRBP binding while allowing some Sp1 to bind
(Fig. 1A; Sp1 and/or IRBP binding also shown in Zhu et al. (14) and Kaytor et al. (23)). In addition, the
enhanced band is supershifted by an antibody against Sp1 (data not
shown). Thus, a factor(s) in hepatic nuclear extracts appears to act
via the AT-rich element to facilitate Sp1 interactions with region V.
Facilitation of Sp1 Binding Occurs Even If the GC-rich Element Is a
Consensus Sp1 Site--
The GC-rich element in IGF-I region V contains
a 1-bp mutation from the consensus Sp1 site (16) with a T substituted
for a C (Table I). We examined binding with region V probes mutated to
contain the consensus Sp1 site both with an intact AT-rich element and
with a mutated AT-rich element (VcSp1 and VmATcSp1, Table I). As
expected, rhSp1 interacted more strongly with the VcSp1 probe than with
the wtV probe in gel shift studies (Fig. 5A, lanes 2 and
3). Similar to the results obtained with the wtV and VmAT
probes, binding of rhSp1 to the VmATcSp1 probe mutated in the AT-rich
site was weaker than binding to the VcSp1 probe with the intact AT-rich
site (Fig. 5B). Although Sp1 bound more strongly to the
VcSp1 probe, facilitation by a factor(s) in nuclear extracts was still
observed with VcSp1 (Fig. 5C, lane 3),
demonstrating that the presence of a consensus Sp1 site did not
eliminate the potential of other factors to enhance Sp1 binding.
Positioning of the AT-rich and GC-rich Elements Is Critical for
Facilitation--
Facilitation of Sp1 binding to the GC-rich element
may be mediated by physical interactions of Sp1 with a factor such as
IRBP that binds to the AT-rich element; such interactions could promote or stabilize Sp1 binding and action. To investigate this possibility, we performed gel shift studies with region V probes containing 2-, 5-, and 10-bp insertions between the AT-rich and GC-rich elements (V+2,
V+5, and V+10, Table I). As shown in Fig.
6, facilitation of Sp1 binding by a
factor(s) in nuclear extracts occurred as long as the AT-rich and
GC-rich sites were positioned close to their native positions with
regard to the face of the DNA helix; the insertion of either 2 or 10 bp
into region V did not inhibit facilitation, whereas a 5-bp insertion
that introduced a 180° alteration in the relative positioning of the
two sites completely abolished facilitation. The spatial relationship
of the AT-rich and GC-rich elements is thus important for the
interaction between the sites that occurs in vitro.
The importance of the spacing between the two sites was also tested in
transient transfection studies. HepG2 hepatoma cells were cotransfected
with luciferase reporter plasmids containing four copies of the wtV,
VcSp1, V+2, V+5, and V+10 sequences together with either an Sp1
expression plasmid or the empty vector (pPac). As shown in Fig.
7, activity of both the wtV and the VcSp1
control reporters was stimulated by the Sp1 expression vector. However, although insertions of 2 or 10 bp did not affect facilitation of Sp1
binding in vitro (Fig. 6), insertion of either 2, 5, or 10 bp prevented activation by Sp1 in vivo (Fig. 7). Therefore, the spatial relationship between the two elements is even more critical
in vivo.
IRBP May Be the Nuclear Factor That Facilitates Sp1 Binding to
Region V--
We previously demonstrated that an insulin-responsive
nuclear factor(s), IRBP, binds to region V at the AT-rich element (23). To determine whether IRBP might be the factor that facilitates Sp1
binding, we conducted gel shift analyses using the wtV probe and
threshold amounts of rhSp1 and nuclear extracts from CHO-IR cells
treated with or without 10 Diabetes-related regulation of IGF-I gene transcription appears to
involve region V, a DNase I footprint site located downstream from the
major transcription initiation sites in exon 1 (13). Region V contains
both a GC-rich element that is a functional Sp1 site (14) and an
AT-rich element immediately adjacent to the GC-rich element. Our
examination of insulin-mediated IGF-I expression led to the detection
of IRBP, an insulin-responsive complex that binds to the AT-rich
element (23). The present studies show that binding of hepatic nuclear
extracts to region V probes is diminished either by mutations in the
AT-rich element or by the addition of berenil, which blocks DNA-protein
interactions involving AT-rich sequences. The AT-site mutations and
berenil also reduce both binding of recombinant Sp1 to region V probes in vitro and the ability of Sp1 to transactivate IGF-I
reporter constructs in vivo. Sp1 binding to region V is
therefore at least partially dependent on the presence of the AT-rich element.
The requirement of neighboring sequences to facilitate transcription
factor binding is well recognized (28). However, our studies of
facilitation of Sp1 binding by nuclear extracts indicate that the
presence of the AT-rich element may also be important in permitting
binding of a nuclear factor(s) such as IRBP, which in turn enhances Sp1
binding. The possibility of physical interaction between Sp1 and a
factor such as IRBP was shown by the spatial dependence of
facilitation; insertion of 5 bp between the AT-rich and GC-rich
elements abolished facilitation, but facilitation persisted with 2- and
10-bp insertions that would maintain the AT-rich and GC-rich elements
on the same side of the DNA helix. Since the insertion of 2, 5, or 10 additional base pairs between the AT-rich and GC-rich sequences
abrogated the ability of Sp1 to activate reporter constructs in
vivo, it is likely that facilitation of Sp1 activation or
recruitment of nuclear factors that contribute to the transcriptional
machinery may have more stringent requirements than facilitation of Sp1
DNA binding alone. Furthermore, a physical interaction between Sp1 and
a factor such as IRBP is supported by the observation that facilitation
of Sp1 binding to region V is greater with nuclear extracts from
insulin-treated cells than with extracts from untreated cells.
Sp1 has been implicated in the expression of a large number of genes,
most often in conjunction with other transcription factors that provide
specificity. For example, stimulation of gene transcription by the
sterol response element binding protein, which mediates the expression
of a number of genes involved in cholesterol biosynthesis and uptake
and fatty acid synthesis (reviewed in Ref. 29), often requires the
presence of additional factors, including Sp1 (30-32). In addition,
Sp1 has been shown to cooperate with a plethora of other transcription
factors such as AP1, E2F, c-Jun, NF-Y, Elk-1, and the Smad proteins to
control the expression of a diverse group of genes (19, 20, 21, 34).
Thus, Sp1 appears to have a wide role as a cofactor in the
transcriptional regulation of many genes; our data support the
hypothesis that IGF-I is another example of such a gene.
The consensus binding site for Sp1 consists of the sequence
5'-CCGCCC-3' (16), whereas the Sp1 binding site within region V
contains the sequence 5'-CTGCCC-3'. We hypothesize that this 1-bp
difference from the consensus site may render Sp1 binding and activity
more dependent on the presence of a factor(s) such as IRBP, which binds
to the neighboring AT-rich element; when insulin levels are high, IRBP
binding at the AT-rich element could promote interactions with Sp1 and
stimulate IGF-I expression. Consistent with our hypothesis, we observed
greater binding of Sp1 to a region V probe containing a consensus Sp1
site as compared with the wild type sequence, and although facilitation
of Sp1 binding by nuclear extracts was still observed with the VcSp1 probe, facilitation was less that with the wtV probe.
It is possible that nuclear extracts could facilitate Sp1 binding by
altering the status of Sp1 phosphorylation. Depending on the gene,
phosphorylation can result in either increased or decreased binding to
DNA probes (35-38). Daniel et al. (33) demonstrate that Sp1
is involved in glucose-mediated regulation of the acetyl-CoA carboxylase gene and that dephosphorylation of Sp1 upon glucose treatment results in greater DNA binding and transcriptional
activation. To test the possibility that facilitation in the present
studies reflects changes in Sp1 phosphorylation, we conducted gel shift studies using nuclear extracts or rhSp1 treated with either alkaline phosphatase or the phosphatase inhibitor okadaic acid. Since we were
unable to demonstrate a consistent effect of either phosphorylation or
dephosphorylation on the binding of Sp1 to region V (data not shown),
it is unlikely that the potential role of insulin in modulating Sp1
effects on IGF-I transcription involves changes in Sp1 phosphorylation status. However, since some (weaker) facilitation was observed with
probes lacking the AT-rich element (Fig. 4), it remains possible that
some facilitation may occur via protein-protein interactions and/or
post-translational modifications that do not involve binding to the
AT-rich element.
Although our data are suggestive, we do not know whether the
facilitation of Sp1 binding to region V is due to IRBP or instead reflects the contributions of another factor. However, binding experiments showing that nuclear extracts from CHO-IR cells treated with 10
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, DNA polymerase, Smad7, and fatty acid
synthase (19-22). These genes encode diverse proteins with a wide
variety of functions, and Sp1 actions alone are not likely to control
expression. Rather, Sp1 appears to act in concert with other
transcription factors that are more specific, such as Elk-1 (19), E2F
(20), AP1 (21), and sterol response element binding protein
(22), to elicit the proper level of expression for these genes.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP
(3000 Ci/mmol) was purchased from Amersham Pharmacia Biotech. Oligonucleotides corresponding to IGF-I region V were obtained from
Life Technologies, Inc., berenil (diminazene aceturate), protease
inhibitors, and other chemicals were purchased from Sigma, and
recombinant human Sp1 (rhSp1) was purchased from Promega (Madison, WI).
DNA modifying enzymes were from New England Biolabs (Beverly, MA).
3 Prime, Inc., Boulder, CO). Medium was replaced 2-3 h
after transfection and again after 24 h. Cells were harvested for
luciferase assays 48 h after transfection. When included, berenil
was used at 500 nM. HepG2 cells were transfected overnight
with the Targefect F2 reagent (Targeting Systems, San Diego, CA) and
harvested for luciferase measurement ~36 h after transfection.
Results were normalized to total protein concentration.
4 M HCl before
use. CHO-IR cells were cultured in F-12 medium containing 10% fetal
bovine serum with or without 10
6 M insulin
for 24 h. Nuclear extracts were prepared using the method of
Schreiber et al. (26). Briefly, cells were washed with
phosphate-buffered saline, scraped, pelleted, and resuspended in Buffer
A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin). After swelling on ice, cells were lysed by the
addition of Nonidet P-40. Nuclei were pelleted, resuspended in Buffer B
(20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin), and lysed by vigorous shaking on a Vortex mixer.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
IGF-I region V oligonucleotide
sequences

View larger version (58K):
[in a new window]
Fig. 1.
The AT-rich element is important for nuclear
extract binding to region V. Rat liver nuclear extracts were
incubated with region V probes for electrophoretic mobility shift
analysis. Panel A, probes contained either the wtV or VmAT
sequence, as indicated. Panel B, the wtV probe was
preincubated with berenil for 30 min before the addition of nuclear
extracts (NE). Similar results were obtained in three
additional experiments.

View larger version (27K):
[in a new window]
Fig. 2.
The AT-rich element is critical for
interactions of Sp1 with region V in vitro.
Recombinant Sp1 was incubated with region V probes for mobility shift
studies. Panel A, probes corresponded to either wtV, VmAT,
or VmSp1, as indicated. Panel B, the wtV probe was
preincubated with berenil for 30 min before the addition of rhSp1.
Similar results were obtained in four additional experiments.

View larger version (53K):
[in a new window]
Fig. 3.
The AT-rich element is important for region V
activation by Sp1 in transfection studies. Panel A, CHO
cells were cotransfected with pGL3 luciferase reporter constructs
containing three tandem copies of the wtV, VmAT, or VmSp1 sequences
together with either a pPac expression vector encoding Sp1 or the empty
vector control. Samples were harvested 48 h after transfection and
assayed for luciferase activity. Panel B, transfected cells
were incubated with 500 nM berenil for 48 h after
transfection, and extracts were assayed for luciferase activity. Data
represent the means ± S.E. for three separate experiments.

View larger version (31K):
[in a new window]
Fig. 4.
Hepatic nuclear extracts facilitate the
interaction of Sp1 with region V. Trace amounts of either nuclear
extracts (NE), rhSp1, or both were incubated with the wtV
and VmAT probes and subjected to electrophoresis. Similar results were
obtained in at least three additional experiments.

View larger version (56K):
[in a new window]
Fig. 5.
Sp1 binds more strongly if region V contains
the consensus Sp1 binding site. Gel shift analysis of interactions
between various region V sequences and rhSp1. Panel A, rhSp1
was incubated with probes corresponding to its consensus binding site
(cSp1), region V containing a consensus Sp1 site
(VcSp1), wtV, and VmAT. Panel B, gel mobility
shift studies with rhSp1 and probes containing the consensus Sp1
sequence in the context of either wtV or VmAT. Panel C,
facilitation studies using trace amounts of nuclear extracts and/or
rhSp1 incubated with the VcSp1 probe. Similar results were obtained in
at least two additional experiments.

View larger version (69K):
[in a new window]
Fig. 6.
The spatial relationship between the AT-rich
and GC-rich elements is critical for facilitation of Sp1 binding to
region V. Gel shift reactions contained trace amounts of hepatic
nuclear extracts (NE) and/or rhSp1 incubated with the wtV
probe or probes containing 2-, 5-, and 10-bp insertions between the
AT-rich and GC-rich sites. Similar results were obtained in two
additional experiments.

View larger version (29K):
[in a new window]
Fig. 7.
The spacing between the AT-rich and GC-rich
elements affects activation by Sp1 in transfection assays. HepG2
cells were cotransfected with reporter plasmids containing four tandem
repeats of region V sequences as indicated together with the Sp1
expression construct or the empty vector control. Cells were
harvested 36 h post-transfection and assayed for luciferase
activity. Results were normalized to total protein and then normalized
to the pGL3 vector control. Data are the means ± S.E. for at
least five separate transfections.
6 M insulin for
24 h. The facilitation of Sp1 binding was ~4-fold greater with
extracts from insulin-treated cells (Fig.
8, lanes 4 and 5,
p < 0.04), suggesting that IRBP may be the factor that binds to the AT-rich sequence and facilitates Sp1 binding to the adjacent GC-rich element.

View larger version (15K):
[in a new window]
Fig. 8.
Nuclear extracts (NE) from
insulin-treated cells exhibit stronger facilitation of rhSp1
binding. CHO-IR cells were incubated in F-12 medium with or
without 10
6 M insulin for 24 h, and
nuclear extracts were prepared. Gel shifts were conducted using the wtV
probe and trace amounts of either the nuclear extracts, rhSp1, or both.
Similar results were obtained in three additional experiments using
different nuclear extract preparations.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
6 M insulin for 24 h provide
greater facilitation than nuclear extracts from untreated cells (Fig.
8) are operationally consistent with a role for IRBP. The
observation of insulin-responsive facilitation combined with
insulin-regulated IGF-I transcription and IRBP binding to region V
support the need for identification of IRBP for future mechanistic studies.
| |
FOOTNOTES |
|---|
* This work was supported in part by National Institutes of Health Grants DK-07298 and DK-09922 (to E. N. K.) and DK-33475 (to L. S. P.). This research was previously presented in part at meetings of the Endocrine Society and the American Society of Biochemistry and Molecular Biology.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Division of
Endocrinology, Emory University School of Medicine, 1639 Pierce Dr., 1301 WMRB, Atlanta, GA 30322. Tel.: 404-727-1391; Fax: 404-727-1300; E-mail: medlsp@emory.edu.
Published, JBC Papers in Press, July 16, 2001, DOI 10.1074/jbc.M104035200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IGF-I, insulin-like growth factor-I; IRBP, insulin-responsive binding protein; rhSp1, recombinant human Sp1; bp, base pair(s); CHO, Chinese hamster ovary; DTT, dithiothreitol; IR, insulin receptor.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Blundell, T. L., Bedarkar, S., and Humbel, R. E. (1983) Fed. Proc. 42, 2592-2597 |
| 2. | Stewart, C. E. H., and Rotwein, P. (1996) Physiol. Rev. 76, 1005-1026 |
| 3. | Schwander, J., Hauri, C., Zapf, J., and Froesch, E. (1983) Endocrinology 113, 297-305 |
| 4. | Sjogren, K., Liu, J. L., Blad, K., Skrtic, S., Vidal, O., Wallenius, V., LeRoith, D., Tornell, J., Isaksson, O. G., Jansson, J. O., and Ohlsson, C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7088-7092 |
| 5. | Daughaday, W. H., and Rotwein, P. (1989) Endocr. Rev. 10, 68-91 |
| 6. | Roberts, C. T., Jr., Brown, A. L., Graham, D. E., Seelig, S., Berry, S., Gabbay, K. H., and Rechler, M. M. (1986) J. Biol. Chem. 261, 10025-10028 |
| 7. | Phillips, L. S., and Kaytor, E. N. (1999) J. Anim. Sci. 77, 43-54 |
| 8. | Goldstein, S., Sertich, G., Levan, K. R., and Phillips, L. S. (1988) Mol. Endocrinol. 2, 1093-1100 |
| 9. | Pao, C.-I, Farmer, P. K., Begovic, S., Goldstein, S., Wu, G.-J., and Phillips, L. S. (1992) Mol. Endocrinol. 6, 969-977 |
| 10. | Pao, C.-I, Farmer, P. K., Begovic, S., Villafuerte, B. C., Wu, G.-J., Robertson, D. G., and Phillips, L. S. (1993) Mol. Endocrinol. 7, 1561-1568 |
| 11. | Adamo, M. L., Ben-Hur, H., LeRoith, D., and Roberts, C. T., Jr. (1991) Biochem. Biophys. Res. Commun. 176, 887-893 |
| 12. | Krishna, A. Y., Pao, C.-I, Thule, P. M., Villafuerte, B. C., and Phillips, L. S. (1996) J. Endocrinol. 151, 215-223 |
| 13. | Pao, C.-I, Zhu, J.-L., Robertson, D. G., Lin, K. W. M., Farmer, P. K., Begovic, S., Wu, G.-J., and Phillips, L. S. (1995) J. Biol. Chem. 270, 24917-24923 |
| 14. | Zhu, J. L., Pao, C.-I, Kaytor, E. N., and Phillips, L. S. (2000) Mol. Cell. Endocrinol. 164, 205-218 |
| 15. | Gehring, W. J., Qian, Y. Q., Billeter, M., Furukubo-Tokunaga, K., Schier, A. F., Resendez-Perez, D., Affolter, M., Otting, G., and Wüthrich, K. (1994) Cell 78, 211-223 |
| 16. | Briggs, M. R., Kadonaga, J. T., Bell, S. P., and Tjian, R. (1986) Science 234, 47-52 |
| 17. | Hagen, G., Müller, S., Beato, M., and Suske, G. (1992) Nucleic Acids Res. 20, 5519-5525 |
| 18. | Kingsley, C., and Winoto, A. (1992) Mol. Cell. Biol. 12, 4251-4261 |
| 19. | Tsai, E. Y., Falvo, J. V., Tsytsykova, A. V., Barczak, A. K., Reimold, A. M., Glimcher, L. H., Fenton, M. J., Gordon, D. C., Dunn, I. F., and Goldfeld, A. E. (2000) Mol. Cell. Biol. 20, 6084-6094 |
| 20. | Izumi, M., Yokoi, M., Nishikawa, N. S., Miyazawa, H., Sugino, A., Yamagishi, M., Yamaguchi, M., Matsukage, A., Yatagai, F., and Hanaoka, F. (2000) Biochim. Biophys. Acta 1492, 341-352 |
| 21. | Brodin, G., Ahgren, A., ten Dijke, P., Heldin, C. H., and Heuchel, R. (2000) J. Biol. Chem. 275, 29023-29030 |
| 22. | Bennett, M. K., Lopez, J. M., Sanchez, H. B., and Osborne, T. F. (1995) J. Biol. Chem. 270, 25578-25583 |
| 23. | Kaytor, E. N., Zhu, J. L., Pao, C.-I, and Phillips, L. S. (2001) Endocrinology 142, 1041-1049 |
| 24. | Courey, A. J., and Tjian, R. (1988) Cell 55, 887-898 |
| 25. | Lavery, D. J., and Schibler, U. (1993) Genes Dev. 7, 1871-1884 |
| 26. | Schreiber, E., Matthias, P., Müller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419-6419 |
| 27. | Gresch, N., and Pullman, B. A (1984) Mol. Pharmacol. 25, 452-458 |
| 28. | Fry, C. J., and Farnham, P. J. (1999) J. Biol. Chem. 274, 29583-29586 |
| 29. | Brown, M. S., and Goldstein, J. L. (1997) Cell 89, 331-340 |
| 30. | Sanchez, H. B., Yieh, L., and Osborne, T. F. (1995) J. Biol. Chem. 270, 1161-1169 |
| 31. | Dooley, K. A., Bennett, M. K., and Osborne, T. F. (1999) J. Biol. Chem. 274, 5285-5291 |
| 32. | Magana, M. M., Koo, S. H., Towle, H. C., and Osborne, T. F. (2000) J. Biol. Chem. 275, 4726-4733 |
| 33. | Daniel, S., Zhang, S., DePaoli-Roach, A. A., and Kim, K.-H. (1996) J. Biol. Chem. 271, 14692-14697 |
| 34. | Chen, B. K., and Chang, W. C. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10406-10411 |
| 35. | Leggett, R. W., Armstrong, S. A., Barry, D., and Mueller, C. R. (1995) J. Biol. Chem. 270, 25879-25884 |
| 36. | Armstrong, S. A., Barry, D. A., Leggett, R. W., and Mueller, C. R. (1997) J. Biol. Chem. 272, 13489-13495 |
| 37. | Zutter, M. M., Ryan, E. E., and Painter, A. D. (1997) Blood 90, 678-689 |
| 38. | Merchant, J. L., Du, M., and Todisco, A. (1999) Biochem. Biophys. Res. Commun. 254, 454-461 |
This article has been cited by other articles:
![]() |
R. P. Rhoads, J. W. Kim, B. J. Leury, L. H. Baumgard, N. Segoale, S. J. Frank, D. E. Bauman, and Y. R. Boisclair Insulin Increases the Abundance of the Growth Hormone Receptor in Liver and Adipose Tissue of Periparturient Dairy Cows J. Nutr., May 1, 2004; 134(5): 1020 - 1027. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Li, Y.-H. Chen, T.-J. Liu, J. Jia, S. Hampson, Y.-X. Shan, D. Kibler, and P. H. Wang Using DNA Microarray to Identify Sp1 as a Transcriptional Regulatory Element of Insulin-Like Growth Factor 1 in Cardiac Muscle Cells Circ. Res., December 12, 2003; 93(12): 1202 - 1209. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D'Addario, P. D. Arora, R. P. Ellen, and C. A. G. McCulloch Interaction of p38 and Sp1 in a Mechanical Force-induced, beta 1 Integrin-mediated Transcriptional Circuit That Regulates the Actin-binding Protein Filamin-A J. Biol. Chem., November 27, 2002; 277(49): 47541 - 47550. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |